http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
안창남,우규진,김태연,신광순,김철중,백락주,An, Chang-Nam,Woo, Gyu-Jin,Kim, Tae-Yeon,Shin, Kwang-Soon,Kim, Chul-Joong,Baek, Luck-Ju 대한미생물학회 1996 Journal of Bacteriology and Virology Vol.26 No.2
Rickettsia tsutsugamushi의 원형균주인 Karp주와 Gilliam주를 초대 배양된 사람 정상 2배체 폐세포(LuMA cell)를 이용하여 증식과 세포병변들의 속도를 비교할 수 있었고, 배양된 균주는 네스티드 프라이머를 사용하여 혈청형을 동정할 수 있었다. R. tsutsugamushi의 세포벽 외막에 존재하며 혈청형을 결정하는 주요항원은 54-56Kd 단백인 것으로 밝혀지고 있는데, 이 단백 유전자의 DNA 염기서열을 분석하여 Karp주와 Gilliam주의 공통서열로 첫번째 프라이머쌍을 만들었고 첫번째 프라이머쌍의 안쪽에 위치한 혈청형 사이에 차이가 있는 서열로 두번째 프라이머쌍을 만들었다. 네스티드 뉴클레오티드 프라이머는 중합효소 연쇄반응의 특이성을 증가시킬 수 있는데 이 실험 결과로 이 PCR 방법은 scrub typhus의 진단과 혈청형의 동정에 적용될 수 있을 것으로 보여진다. We selected the adequate cell line to be used for propagation and plaquing of R. tsutsugamushi in laboratory and identified R. tsutsugamushi serotype cultured in LuMA cells by nested PCR. As in this study, we concluded that. 1. LuMA cell was suitable for the study of the biology of rickettsiae-host cell interaction. 2. The plaque-forming unit (PFU) per ml of R. tsutsugamushi Karp strain propagated in embryonated egg yolk sacs was $10^{8.8}$ and the PFU/ml of Gilliam strain was $10^{7.1}$. 3. The rate and extent of cytopathic changes depended on the PFU titer of R. tsutsugamushi. 4. PCR with nested primer pairs was useful for identification of R. tsutsugamushi serotype cultured in human embryonic lung cells.
$1996{\sim}1998$년 유고슬라비아에서 실시한 한탄바이러스 불활화 백신($Hantavax^{TM}$)의 면역효과에 대한 야외시험
주용규,우영대,안창남,김훈,장양석,박승철,김민자,이은실,이호왕,Chu, Yong-Kyu,Gligic, Anna,Tomanovic, Snezana,Bozovjc, Boyana,Obradovic, Mirceta,Woo, Young-Dae,An, Chang-Nam,Kim, Hun,Jiang, Yang-Seok,Park, Seung-Chul,Kim, Min-Ja 대한미생물학회 1999 Journal of Bacteriology and Virology Vol.28 No.1
In Yugoslavia, hemorrhagic fever with renal syndrome (HFRS) is one of the important national health problem, but no vaccine has been used to prevent HFRS. Since first HFRS case in 1952, sporadic cases of HFRS occurred every year and over 4,000 registered cases with $1{\sim}16%$ mortality so far. We performed a prospective, randomized double-blind placebo-controlled trial to evaluate the effectiveness of $Hantavax^{TM}$ against HFRS in 3,900 healthy adults living in the endemic areas of Yugoslavia. 1,900 people were given 0.5 ml of Hantavax subcutaneously twice at one month interval and a booster shot at one year after. For controls other 2,000 healthy people were given 0.5 ml of physiolosical saline as a placebo. We investigated HFRS cases in both the vaccinated and nonvaccinated groups by monitoring the program for patient registration in the areas from 1996 to 1998, and the effect of vaccine was analyzed epidemiologically. No confirmed case of HFRS was observed among 1,900 Hantavax vaccinees, while 20 confirmed cases were observed among 2,000 nonvaccinated control group. There were no remarkable side effects among the vaccinees either locally or in general after inoculation of the vaccine. The Hantavax vaccine showed statistically significant protective efficacy against HFRS among Yugoslavian people.